NASH drug developers in the red after Madrigal's mid-stage success with MGL-3196 Dec. 6, 2017 12:37 PM ET|By: Douglas W. House, SA News Editor Investors are swarming over Madrigal Pharmaceuticals (MDGL +79.8%) after it reported positive results from a Phase 2 clinical trial assessing MGL-3196 in NASH patients. Certain would-be NASH players have been brushed aside in early trading. Selected tickers: (MNOV +0.9%)(GLMD)(RGLS -2.2%)(ICPT +0.4%)(CNAT -2.4%)(VBLT +1.6%)(GALT -8.7%)(SHPG -1.5%)(AGN +0.3%)(HZNP -1.2%)(OTCPK:GNFTF -5%)(VKTX +2.6%)
I'm not familiar with MDGL's entry...whether it's a targeted approach for a single issue (NASH), or a multi-faceted potential like CNAT. CNAT's game is for combination therapies focused on multiple liver issues not exclusively NASH. From CNAT Website:
I believe the next potential Novartis payment will be a "milestone" payment of which the criteria used to determine its implementation has never been clarified or identified... to the best of my knowledge anyway.
It would be nice to wake some morning with a PR stating that they have, in fact, issued a check for some benchmark reached...
I added today below 3.97. There was no whole-sale sell-off which suggests to me that confused/nervous money exited after MDGL's phase IIb success without really understanding the implications.